A Unique Clinical Presentation of an Emerging Invasive Fungal Infection in a Hospitalized Patient: the Lessons Learned

Omotayo Olatinwo^{1, 2,} , Yugandhara Devarapalli^{1, 2} and M.D Gary Smith^{3, 2}

¹Sound Physicians, CHRISTUS St. Frances Cabrini, Alexandria, Louisiana, USA

²CHRISTUS St. Frances Cabrini Hospital, Alexandria, Louisiana, USA

³CHRISTUS Cabrini Intensivists Group, Alexandria, Louisiana, USA

Cite this paper

Omotayo Olatinwo, Yugandhara Devarapalli and M.D Gary Smith. A Unique Clinical Presentation of an Emerging Invasive Fungal Infection in a Hospitalized Patient: the Lessons Learned. American Journal of Medical Case Reports. 2020; 8(3):91-97. doi: 10.12691/AJMCR-8-3-7

Abstract

Invasive Saccharomyces cerevisiae infection is a rare and emerging fungal infection. The emergence of this invasive infection is due to the increased use of Saccharomyces boulardii probiotics. Saccharomyces boulardii probiotics are biotherapeutic agents used for the prevention and treatment of various diarrheal diseases. The benefits of these probiotics are well established; however, its associated infectious complications seem underestimated, especially in at-risk patients. Like other rare invasive yeast infections, invasive Saccharomyces infection has a high mortality rate. A 67-year-old man with multiple medical comorbidities and a complicated hospital course received Saccharomyces boulardii probiotics via percutaneous endoscopic gastrostomy tube for 22 days for Clostridium difficile prophylaxis treatment. We diagnosed him with invasive Saccharomyces cerevisiae fungemia resulting from Saccharomyces cerevisiae peritonitis. He developed multiple organ failure and shock, which led to his death 27 days after his first dose of Saccharomyces boulardii probiotics. To the best of our knowledge, we report the first case of invasive Saccharomyces cerevisiae fungemia due to Saccharomyces cerevisiae peritonitis caused by the combination of percutaneous endoscopic gastrostomy (PEG) tube placement and PEG tube administration of Saccharomyces boulardii probiotics in an at-risk hospitalized patient. Our goals for reporting this case are to heighten the index of clinical suspicion of invasive Saccharomyces fungemia, discuss the lessons we learned, and revisit the literature on the management of invasive Saccharomyces infection in at-risk hospitalized patients.

Keywords

invasive Saccharomyces cerevisiae, emerging fungal infection, Saccharomyces boulardii probiotics, Saccharomyces cerevisiae fungemia, Saccharomyces cerevisiae peritonitis, transmigration, hospital-acquired transmission

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	McFarland, L. V. (2010). Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World journal of gastroenterology: WJG, 16(18), 2202.
[2]	Kelesidis, T., & Pothoulakis, C. (2012). Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therapeutic advances in gastroenterology, 5(2), 111-125.
[3]	Hempel, S., Newberry, S., & Ruelaz, A. Safety of Probiotics to Reduce Risk and Prevent or Treat Disease. US Department of Health and Human Services, 2011.
[4]	Enache-Angoulvant, A., & Hennequin, C. (2005). Invasive Saccharomyces infection: a comprehensive review. Clinical Infectious Diseases, 41(11), 1559-1568.
[5]	Munoz, P., Bouza, E., Cuenca-Estrella, M., Eiros, J. M., Pérez, M. J., Sánchez-Somolinos, M., ... & Peláez, T. (2005). Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clinical Infectious Diseases, 40(11), 1625-1634.
[6]	Costa, R. L., Moreira, J., Lorenzo, A., & Lamas, C. C. (2018). Infectious complications following probiotic ingestion: a potentially underestimated problem? A systematic review of reports and case series. BMC complementary and alternative medicine, 18(1), 329.
[7]	Taylor, G. D., Buchanan-Chell, M., Kirkland, T., & McKenzie, M. (1994). Trends and sources of nosocomial fungaemia: Trends und Ursprünge nosokomialer Fungämien. Mycoses, 37(5-6), 187-190.
[8]	Lherm, T., Monet, C., Nougière, B., Soulier, M., Larbi, D., Le Gall, C., ... & Malbrunot, C. (2002). Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive care medicine, 28(6), 797-801.
[9]	Piarroux, R., Millon, L., Bardonnet, K., Vagner, O., & Koenig, H. (1999). Are live saccharomyces yeasts harmful to patients? The Lancet, 353(9167), 1851-1852.
[10]	Gareau, M. G., Sherman, P. M., & Walker, W. A. (2010). Probiotics and the gut microbiota in intestinal health and disease. Nature reviews Gastroenterology & hepatology, 7(9), 503.
[11]	Szajewska, H., Setty, M., Mrukowicz, J., & Guandalini, S. (2006). Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy. Journal of pediatric gastroenterology and nutrition, 42(5), 454-475.
[12]	Kwon-Chung, K. J., & Bennett, J. E. (1992). Medical mycology. Revista do Instituto de Medicina Tropical de São Paulo, 34(6), 504-504.
[13]	Salonen, J. H., Richardson, M. D., Gallacher, K., Issakainen, J., Helenius, H., Lehtonen, O. P., & Nikoskelainen, J. (2000). Fungal colonization of haematological patients receiving cytotoxic chemotherapy: emergence of azole-resistant. Saccharomyces cerevisiae. Journal of Hospital Infection, 45(4), 293-301.
[14]	Greer, A. E., & Gemoets, H. N. (1943). The coexistence of pathogenic fungi in certain chronic pulmonary diseases: with especial reference to pulmonary tuberculosis (a preliminary report). Diseases of the Chest, 9(3).
[15]	Hennequin, C., Thierry, A., Richard, G. F., Lecointre, G., Nguyen, H. V., Gaillardin, C., & Dujon, B. (2001). Microsatellite typing as a new tool for identification of Saccharomyces cerevisiae strains. Journal of clinical microbiology, 39(2), 551-559.
[16]	McCullough, M. J., Clemons, K. V., McCusker, J. H., & Stevens, D. A. (1998). Species Identification and Virulence Attributes ofSaccharomyces boulardii (nom. inval.). Journal of clinical microbiology, 36(9), 2613-2617.
[17]	Hennequin, C., Kauffmann-Lacroix, C., Jobert, A., Viard, J. P., Ricour, C., Jacquemin, J. L., & Berche, P. (2000). Possible role of catheters in Saccharomyces boulardii fungemia. European Journal of Clinical Microbiology and Infectious Diseases, 19(1), 16-20.
[18]	Fiore, N. F., Conway, J. H., West, K. W., & Kleiman, M. B. (1998). Saccharomyces cerevisiae infections in children. The Pediatric infectious disease journal, 17(12), 1177-1179.
[19]	Perapoch, J., Planes, A. M., Querol, A., Lopez, V., Martinez-Bendayan, I., Tormo, R., ... & Salcedo, S. (2000). Fungemia with Saccharomyces cerevisiae in two newborns, only one of whom had been treated with ultra-levura. European Journal of Clinical Microbiology and Infectious Diseases, 19(6), 468-470.
[20]	Ipson, M. A., & Blanco, C. L. (2001). Saccharomyces cerevisiae sepsis in a 35-week-old premature infant. A case report. Journal of Perinatology, 21(7).
[21]	Atıcı, S., Soysal, A., Cerit, K. K., Yılmaz, Ş., Aksu, B., Kıyan, G., & Bakır, M. (2017). Catheter-related Saccharomyces cerevisiae Fungemia Following Saccharomyces boulardii Probiotic Treatment: In a child in intensive care unit and review of the literature. Medical mycology case reports, 15, 33-35.
[22]	Vandenplas, Y., Brunser, O., & Szajewska, H. (2009). Saccharomyces boulardii in childhood. European journal of pediatrics, 168(3), 253-265.
[23]	Cassone, M., Serra, P., Mondello, F., Girolamo, A., Scafetti, S., Pistella, E., & Venditti, M. (2003). Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. Journal of clinical microbiology, 41(11), 5340-5343.
[24]	Graf, C., & Gavazzi, G. (2007). Saccharomyces cerevisiae fungemia in an immunocompromised patient not treated with Saccharomyces boulardii preparation. Journal of Infection, 54(3), 310-311.
[25]	Olver, W. J., James, S. A., Lennard, A., Galloway, A., Roberts, I. N., Boswell, T. C., & Russell, N. H. (2002). Nosocomial transmission of Saccharomyces cerevisiae in bone marrow transplant patients. Journal of Hospital Infection, 52(4), 268-272.
[26]	Ren, P., Sridhar, S., & Chaturvedi, V. (2004). Use of paraffin-embedded tissue for identification of Saccharomyces cerevisiae in a baker's lung nodule by fungal PCR and nucleotide sequencing. Journal of clinical microbiology, 42(6), 2840-2842.
[27]	Pillai, U., Devasahayam, J., Kurup, A. N., & Lacasse, A. (2014). Invasive Saccharomyces cerevisiae infection: A friend turning foe?. Saudi Journal of Kidney Diseases and Transplantation, 25(6), 1266.
[28]	Bernstein, C. N., Orr, K., Blanchard, J. F., Sargent, M., & Workman, D. (2001). Development of an assay for antibodies to Saccharomyces cerevisiae: easy, cheap and specific for Crohn's disease. Canadian Journal of Gastroenterology and Hepatology, 15(8), 499-504.
[29]	DOUGHERTY, S. H., & SIMMONS, R. L. (1982). Postoperative peritonitis caused by Saccharomyces cerevisiae. Archives of Surgery, 117(2), 248-249.
[30]	Snyder, S. (1992). Peritonitis due to Saccharomyces cerevisiae in a patient on CAPD. Peritoneal Dialysis International, 12(1), 77-78.
[31]	Backert, S., Boehm, M., Wessler, S., & Tegtmeyer, N. (2013). Transmigration route of Campylobacter jejuni across polarized intestinal epithelial cells: paracellular, transcellular or both? Cell Communication and Signaling, 11(1), 72.
[32]	Okahashi, N., Nakata, M., Kuwata, H., & Kawabata, S. (2016). Streptococcus oralis induces lysosomal impairment of macrophages via bacterial hydrogen peroxide. Infection and immunity, 84(7), 2042-2050.
[33]	Swain, B., & Otta, S. (2013). Streptococcus mitis: an unusual causative agent for urinary tract infection. Journal of laboratory physicians, 5(2), 144.
[34]	Arendrup, M. C., Boekhout, T., Akova, M., Meis, J. F., Cornely, O. A., Lortholary, O., & ESCMID EFISG study group and ECMM. (2014). ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clinical Microbiology and Infection, 20, 76-98.
[35]	Arendrup, M. C., Dzajic, E., Jensen, R. H., Johansen, H. K., Kjaldgaard, P., Knudsen, J. D., ... & Olesen, B. (2013). Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clinical Microbiology and Infection, 19(8), e343-e353.
[36]	Lolis, N., Veldekis, D., Moraitou, H., Kanavaki, S., Velegraki, A., Triandafyllidis, C., ... & Pneumatikos, I. (2008). Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin. Critical Care, 12(2), 414.
[37]	Choi, G., Meijer, S. L., & Hazenberg, M. D. (2012). Disseminated bread yeast fungaemia in a baker's wife with acute myeloid leukaemia. British journal of haematology, 158(3), 298.
[38]	EFSA Panel on Biological Hazards (BIOHAZ). (2013). Scientific Opinion on the maintenance of the list of QPS biological agents intentionally added to food and feed (2013 update). EFSA Journal, 11(11), 3449.
[39]	Tiballi, R. N., Spiegel, J. E., Zarins, L. T., & Kauffman, C. A. (1995). Saccharomyces cerevisiae infections and antifungal susceptibility studies by colorimetric and broth macrodilution methods. Diagnostic microbiology and infectious disease, 23(4), 135-140.
[40]	Arendrup, M. C., Bruun, B., Christensen, J. J., Fuursted, K., Johansen, H. K., Kjældgaard, P., ... & Rosenvinge, F. S. (2011). National surveillance of fungemia in Denmark (2004 to 2009). Journal of clinical microbiology, 49(1), 325-334.
[41]	Hamoud, S., Keidar, Z., & Hayek, T. (2011). Recurrent Saccharomyces cerevisiae fungemia in an otherwise healthy patient. The Israel Medical Association journal: IMAJ, 13(9), 575.